Padua Score to predict VTE risk in thoracic surgery patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates how well the Padua Prediction Score predicts venous thromboembolism in hospitalized thoracic surgery patients. Participants will have their PPS assessed during admission and will be followed postoperatively to identify VTE events. The study focuses on Iraqi hospital settings, aiming to see if PPS can help tailor VTE prevention in this context. Eligibility includes adults with a preoperative PPS assessment, a hospital stay longer than 3 days, and postoperative follow-up feasibility. Exclusions include prior VTE, active anticoagulation, and lack of postoperative D-dimer testing, among others.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who have undergone preoperative Padua Prediction Score assessment.
* Inpatients with a hospital stay over 3 days
* Written informed consent obtained from patients or their legal guardians.
* Availability for postoperative follow-up to assess outcomes like LEVT development or related complications.

Exclusion Criteria:

* Preexisting LEVT or pulmonary embolism.
* Severe Coagulopathy: Patients with inherited or acquired bleeding disorders (e.g., hemophilia, advanced liver disease).
* receiving any anticoagulation therapy for any reason.
* patients who did not undergo a postoperative D-dimer test.
* Incomplete Data: missing essential clinical or laboratory data.
* Pregnancy: pregnant women or those within six weeks postpartum.
* Noncompliance: Patients unwilling or unable to adhere to study follow-up protocols.

Where it's running

• College of Medicine - Al-Nahrain University
  Baghdad, Kadhimiya, Iraq Recruiting

Study contacts

• Study coordinator: Abdul-Ilah R. Khamis
• Email: allaabed987@ced.nahrainuniv.edu.iq
• Phone: +9647838571013

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rivaroxaban vs Enoxaparin After Cesarean Section: Thromboprophylaxis Lab Outcomes

  This study tests whether rivaroxaban taken by mouth once daily after cesarean section provides a similar lab profile for blood clot prevention as enoxaparin given as a daily shot in eligible postpartum women.

  Recruiting Wolfson Medical Center · Holon · NCT07820670

• Iliac vein stenting with dedicated venous stents for chronic post-thrombotic venous ulcers

  This study tests whether using dedicated iliac venous stents to reopen obstructed veins helps heal chronic leg ulcers caused by post-thrombotic syndrome in adults.

  Recruiting Ain Shams University · Cairo · NCT07762222

• Reduced‑dose apixaban or rivaroxaban versus daily low‑molecular‑weight heparin for people with blood cancers

  This trial will test whether reduced‑dose apixaban or rivaroxaban pills can prevent blood clots as well and as safely as daily low‑molecular‑weight heparin injections in people with hematologic malignancies.

  Recruiting Medical University of Gdansk · Gdansk, Pomeranian Voivodeship · NCT07270263

• Wearable ultrasound sensors for early diagnosis and real-time monitoring

  This project will try a wearable ultrasound sensor to detect and monitor blood clots, heart-failure changes, and continuous bedside issues in ICU patients.

  Recruiting Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07009873

• Apixaban dosing options to prevent blood clots in people with cancer

  This study will test whether taking apixaban once a day, twice a day, or not taking anticoagulants helps prevent blood clots and death in adults with solid tumors or lymphoma who have a Khorana score of 2.

  Recruiting Phase 3 University of Vermont · Burlington, Vermont · NCT07005024

• Rivaroxaban in breast milk after maternal dosing

  This will test how much rivaroxaban passes into breast milk in postpartum people taking either prophylactic (10 mg) or therapeutic (20 mg) doses.

  Recruiting Phase 1 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT06831474

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.